The WHO estimates the average medication adherence rate is 50% in developed nations, though the U.S. trails other countries in reported adherence on Medisafe.…

Eli Lilly

Eli Lilly’s new psoriasis treatment Taltz launches first ads, chasing Novartis’ Cosentyx lead

NICE backs 'less-effective' Otezla to give psoriatic arthritis patients a pill option

AstraZeneca's SGLT2 contender Forxiga wins broader NICE backing, giving more U.K. patients access

Woe to pharmas that rely on price hikes, analyst says. Who can go without? BMS, Lilly and Regeneron, for three

Eli Lilly's Portrazza turned away in final NICE guidance